Myths vs facts: CYP1A2 and Blutzucker

The claim that CYP1A2 genotype directly determines blood sugar levels is a myth. CYP1A2 is an enzyme primarily responsible for metabolizing caffeine and certain drugs. Some studies suggest that in slow caffeine metabolizers (CYP1A2*1F variant), high coffee intake may be weakly associated with increased insulin resistance or impaired glucose tolerance. However, the effects are small, inconsistent, and heavily overshadowed by lifestyle factors such as diet, physical activity, and sleep. There is no strong evidence that CYP1A2 testing is useful for blood sugar optimization. Clinical relevance remains unclear, and most guidelines do not recommend genotype-based adjustments of caffeine intake for glycemic control. Caution is warranted against exaggerated marketing claims that derive personalized diets from weak associations. The fact is: blood sugar is primarily influenced by calorie balance, carbohydrate quality, exercise, and medication – not by a single gene.